A better delivery system brings anti-inflammatory therapies to critical sites
Arthritis flares — the unpredictable and often sudden worsening of arthritis symptoms — can be debilitating. These episodes can make the management of inflammatory arthritis, which includes rheumatoid arthritis and psoriatic arthritis, challenging for patients and physicians.
But investigators at Harvard-affiliated Brigham and Women’s Hospital (BWH) have found that flares may also represent an important opportunity for improving treatment options.
In experiments carried out in the lab, BWH bioengineers have developed a hydrogel — a soft, flexible material that can be loaded with arthritis drugs and injected locally into an inflamed joint. Instead of delivering the drug continuously at a steady rate, the hydrogel is designed to respond to increased disease activity during flares, releasing the drug when symptoms worsen. The team’s laboratory-based findings are published this week in Nature Communications and investigators are working on next steps to bring their technology closer to the clinic.
“Arthritis represents a huge unmet clinical need,” said co-senior author Jeff Karp,a bioengineer and principal investigator at BWH and Harvard Medical School (HMS) professor of medicine. “Although new therapeutics have been developed, many have had systemic, toxic effects. We wanted to design a delivery system that could be efficient, deliver drugs locally, and release drugs in response to inflammation.”
The newly created flare-responsive hydrogel is made from triglycerol monostearate (TG-18), a compound from the Food and Drug Administration’s list of “generally recognized as safe” compounds. TG-18 is a molecule capable of self-assembling, meaning that it can form a gel-like structure comprising fibers. This structure can be easily injected as a suspension. In this study, the TG-18 hydrogel was loaded with triamcinolone acetonide (TA), used here as a model drug, but could potentially be loaded with many other kinds of anti-inflammatory compounds.
“The hydrogel is designed so that drug release is triggered by the activity of specific, arthritis-related enzymes that are increased during flares. To test the TG-18 hydrogel, we exposed the gel to several different kinds of environments mimicking conditions in arthritic joints,” said Nitin Joshi, co-first author on the work and an instructor of medicine at BWH and HMS.
When the gel was incubated in synovial fluid from a healthy human joint, drug release was minimal, but when incubated in synovial fluid from a patient with rheumatoid arthritis, the drug was readily released from the hydrogel. Importantly, the drug supply was not exhausted in one spike of synovial fluid — instead, it could be released in response to multiple spikes over time. The team also tested the hydrogel’s effects on cells from cartilage and joints, and found that it appeared to be safe.
The team further tested the clinical efficacy of the TG-18 hydrogel in a mouse model of inflammatory arthritis. They chose the K/BxN serum transfer model, in which disease severity can be precisely controlled, which allowed them to test the hydrogel in animals with different degrees of arthritis severity. They found that when arthritis was more severe, the locally injected hydrogel degraded more rapidly, corresponding to increased drug release. Swelling and severity of arthritis diminished in response to the drug-loaded hydrogel.
One of the advantages of the hydrogel is that it offers the promise of treating arthritis specifically in the joints where the disease is flaring, rather than delivering a drug throughout the body.
“Local therapy could be a viable treatment option for patients with only one or a few inflamed joints, said co-corresponding author Joerg Ermann, a rheumatologist in the BWH Division of Rheumatology, Immunology, and Allergy and HMS instructor in medicine. “Moreover, if a patient is already on a systemic drug but is experiencing a flare in a limited number of joints, we could specifically treat these joints rather than switching to systemic therapy or adding another systemic drug. Having this option would substantially increase our ability to successfully manage arthritis flares in the clinic.”
The team will continue testing the hydrogel in preclinical models to further validate it, and continue to advance toward human clinical trials. The technology has been licensed by Alivio Therapeutics, which is developing therapies to treat inflammatory disorders via targeted disease immunomodulation.
Learn more: Treating inflammatory arthritis with hydrogel
The Latest on: Inflammatory arthritis
via Google News
The Latest on: Inflammatory arthritis
- Anti-Inflammatory Diet: How It Benefits The Body on December 25, 2018 at 1:26 pm
Though it is not a cure, this diet may help anyone who suffers from a condition associated with inflammation. The Arthritis Foundation, for instance, recommends this eating pattern for rheumatoid arth... […]
- Inflammatory Arthritis and the Gut Microbiome: Do Microbes Hold the Key to New Treatments? on December 25, 2018 at 9:08 am
Research has shown that in healthy states, complex interactions among intestinal microbiota, their metabolic products, and the host modulate the host immune response to maintain homeostasis and preven... […]
- Don’t let arthritis aches slow you down on December 25, 2018 at 2:05 am
Control your weight Maintaining a healthy weight can significantly reduce wear and tear on joints, a frequent cause of arthritis flares. A diet high in anti-inflammatory foods, like omega-3-rich salmo... […]
- Health Authorities Now Warn Inflammation Is the Root Cause of Diseases on December 25, 2018 at 1:37 am
It is worth realizing that heart disease is inflammation of the arteries and arthritis is inflammation of the joints. The main course of action for sufferers is to take medications that aim to ... […]
- Canine Arthritis Treatment: North America is the Dominant Market for due to Increased Consumer Spending on Pets on December 24, 2018 at 9:58 am
Based on the treatment type, the Canine Arthritis Treatment is segmented into non-steroidal anti-inflammatory drugs, opioids and stem cell therapy. The non-steroidal anti-inflammatory drugs is expecte... […]
- This Is How Much Turmeric You Need to Reduce Inflammation on December 23, 2018 at 2:47 am
... research says that taking in at least one gram of curcumin per day is necessary for measurable anti-inflammatory effects, Webster says. The Arthritis Foundation recommends 400 to 600 milligrams (m... […]
- Black Cumin Seed Oil May Help With Inflammation on December 22, 2018 at 12:31 am
Inflammation is linked to a wide variety of diseases and conditions ranging from arthritis to heart disease and cancer; it is the silent killer and keeping it at bay is an important part of staying he... […]
- Newly identified subset of immune cells may be key to fighting chronic inflammation on December 21, 2018 at 6:13 am
These cells can also fuel the destructive inflammation in autoimmune disorders like multiple sclerosis and rheumatoid arthritis. Th17 cells have been known for their functional adaptability ... […]
- This Vitamin Supplement Can Help Prevent Rheumatoid Arthritis on December 20, 2018 at 10:39 am
Research from the University of Birmingham and published in Journal of Autoimmunity is reporting that by getting a steady dose of vitamin D in your diet, you can possibly prevent the onset of "inflamm... […]
via Bing News